BAY86-9596

DRUG2 trials

Sponsors

Life Molecular Imaging SA

Conditions

Diagnostic Imaging

Phase 1

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations

CompletedNCT01089998

Life Molecular Imaging SADiagnostic Imaging

Start: 2010-05-31End: 2011-09-30Updated: 2013-01-21

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

CompletedNCT01297088

Life Molecular Imaging SADiagnostic Imaging

Start: 2011-05-31End: 2011-12-31Updated: 2013-01-21